Hematology & Oncology Fellowship Program

Our 3-year ACGME-accredited program is designed to train leading physicians, academics and researchers in the field of hematology and oncology. Fellows will be immersed in the multidisciplinary care of oncologic and hematologic diseases, learning how to offer optimal, state-of-the-art care and management of patients in the outpatient setting, as well as applying the latest advancements in the field. Upon successful completion of the fellowship program, graduates will be board-eligible for medical oncology and hematology.

An Inside Look at the Hematology and Oncology Fellowship

Program Curriculum

Our innovative 3-year program explores all aspects of hematology and oncology, exposing fellows to extensive clinical and research opportunities.

Throughout the curriculum, fellows will have half-day continuity clinic experience with escalating levels of responsibility in the management of patients. Fellows will have a core lecture series held weekly during the fellowship. There are Multidisciplinary Tumor Boards each week, in which fellows are expected to be active participants.

Also, each month there will be a fellow-run journal club, a hematopathology conference where the fellows present on patients and topics of interest, and a president’s conference led by the president of LCI with the fellows covering various patients and general topics of interest. Fellows will find a flexible curriculum designed to support their career aspirations, whether in patient care or research.

Rotations

A basic breakdown of activities by year is as follows:

Year 1:

• 1 month of a unique month-long introductory course to Hematology/Oncology
• 4 months of outpatient oncology and 2 months of outpatient hematology
• 4 months of inpatient hematology (including 2 months on the malignant hematology service which involves transplant and cellular therapy care and 2 months on the consult service) and 1 month of inpatient oncology

Year 2:

• 2 months of inpatient hematology (including 1 month of consult), and 1 month of inpatient oncology
• 1 month of outpatient hematology and 2 months of outpatient multidisciplinary oncology
• 1 month of research
• 5 months of elective time (research or clinical), determined in conjunction with program directors

Year 3:

• 1 month of supportive oncology
• 1 to 3 months of community and VA- based care
• 9 to 10 months of elective time (research or clinical), determined in conjunction with program directors

During year 3, fellows planning to pursue a career in clinical medicine will have the option to complete additional disease-specific and multidisciplinary clinical rotations, which are organized in disease-specific and multidisciplinary rotations.

During the elective time, fellows may pursue research for up to 15 months. Thus, fellows may have up to 16 months of protected research time (aside from continuity clinic), if deemed appropriate and necessary after discussion with the program directors and research mentor. If their research project has been completed, and especially if fellows plan to pursue careers in clinical medicine, they may continue with further clinical rotations, which are organized in disease-specific and multidisciplinary rotations.

A distinct element of the LCI Hematology and /Medical Oncology fellowship program is the emphasis on multidisciplinary care of patients with malignancies, as demonstrated in the second-year multidisciplinary rotations in thoracic and breast cancers. During these rotations, fellows will primarily rotate with medical oncologists, but will also learn from surgeons, radiation oncologists and other appropriate specialists, such as pulmonologists and genetic counselors. Fellows may participate in similar rotations in other malignancies during the elective time.

Helpful Links